|
|
||||||||
EXPERIMENTAL STUDY |
Department of Biochemistry, Hoshi University School of Pharmacy and Pharmaceutical Sciences, 2-4-41 Ebara, Shinagawa, Tokyo 142-8501, Japan
(Correspondence should be addressed to M Watanabe; Email: mastada{at}hoshi.ac.jp)
Objective: Recent progress supports the importance of local estrogen secretion in human bone tissues to increase and maintain bone mineral density. In a previous study, we reported that the expression of aromatase (CYP19) is dexamethasone (Dex)-dependent and oncostatin M (OSM) increases the expression synergistically with Dex. In the present study, we examined the effects of forskolin (FSK) as another potential synergistic factor.
Results: Co-administration of 100 nM Dex and 10 µM FSK increased aromatase activity 4-fold compared with Dex alone. The results of reverse transcriptase (RT)-PCR suggest that the amount of CYP19 gene transcript was also up-regulated by FSK synergistically with Dex, and that promoter I.4, which is not activated by FSK alone, is activated by FSK synergistically with Dex. The results of RT-PCR also suggest that promoter II, which responds to FSK, was not activated even in the presence of FSK in SV-HFO. The promoter I.4 sequence that was transfected into SV-HFO was activated by FSK synergistically with Dex.
Conclusions: Synergistic up-regulation of aromatase activity, CYP19 gene transcript, and promoter I.4 activity were Dex-dependent and not up-regulated by FSK alone. The results of this work may form the basis of bone-specific estrogen-replacement therapy that increases the estrogen concentration in bone tissue only.
This article has been cited by other articles:
![]() |
H. Odawara, T. Iwasaki, J. Horiguchi, N. Rokutanda, K. Hirooka, W. Miyazaki, Y. Koibuchi, N. Shimokawa, Y. Iino, I. Takeyoshi, et al. Activation of Aromatase Expression by Retinoic Acid Receptor-related Orphan Receptor (ROR) {alpha} in Breast Cancer Cells: IDENTIFICATION OF A NOVEL ROR RESPONSE ELEMENT J. Biol. Chem., June 26, 2009; 284(26): 17711 - 17719. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |